In Depth 13 May 2024
New antidepressants: tackling treatment resistant depression
Take a look at how new antidepressants can more effectively tackle treatment resistant depression compared to more traditional treatments.
depression
- Latest Posts
In Depth 13 Mar 2024
From LSD to healing minds: Where are we standing in psychedelic drug development?
Delve into the growing sector of psychedelic drug development to find out where we are coming from, and where we are standing in the field.
Best in Biotech 17 Aug 2023
Six Toronto-based biotech companies to watch this year
The capital city of the Canadian province of Ontario, Toronto, is home to the Discovery District, a commercial hub that sees biotech and healthcare innovations and companies at its prime. Having witnessed the largest growth in tech jobs in North America between 2015 and 2020, Toronto, like Vancouver, is a significant contributor towards Canada’s life […]
News and Trends 23 Feb 2023
Depression trial gets green light
Beckley Psytech Ltd has received investigational new drug (IND) approval from the U.S. Food and Drug Administration (FDA) for a global multi-site phase IIb study exploring the safety, efficacy and tolerability of two doses of its lead compound, BPL–003, in patients with treatment resistant depression (TRD). BPL-003 is the Beckley Psytech’s novel synthetic formulation of […]
News and Trends 15 Nov 2022
Potential new lead compounds for treatment of depression and anxiety disorders
Currently, various classes of drugs are available for the treatment of mental illnesses – such as depression and anxiety disorders. However, although these drugs have benefits, they can also be associated with adverse side-effects. A research group has conducted a study to identify new drugs that could potentially be used for the treatment of neuropsychiatric […]
News and Trends 15 Nov 2022
Beckley Psytech completes treatment resistant depression and alcohol use disorder study
Beckley Psytech, a private, clinical-stage biotechnology company dedicated to addressing neuropsychiatric conditions through the novel application of psychedelic medicines, has completed its phase I clinical study of BPL-003, a synthetic intranasal formulation of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT), which is under development for treatment resistant depression and alcohol use disorder. The double-blind, randomized, single ascending dose study […]
ADVERTISEMENT
ADVERTISEMENT
News and Trends 24 Oct 2022
Beckley Psytech acquires Eleusis Therapeutics
Beckley Psytech Limited has entered into a definitive agreement to acquire clinical-stage life science company Eleusis Therapeutics Limited in an all equity transaction. Under the terms of the agreement, which has been approved by shareholders, Beckley Psytech has acquired 100% of Eleusis, receiving full developmental and commercial rights for the company’s assets, which will further […]
News and Trends 19 Aug 2022
Axsome Therapeutics’ MDD treatment gets green light from FDA
The U.S. Food and Drug Administration (FDA) has approved Axsome Therapeutics, Inc.’s Auvelity tablets for the treatment of major depressive disorder (MDD) in adults. Auvelity (dextromethorphan HBr -bupropion HCl) is the first and only rapid-acting oral medicine approved for the treatment of MDD with labeling of statistically significant antidepressant efficacy compared to placebo starting at […]
News and Trends 15 Aug 2022
Approval for Small Pharma major depressive disorder clinical trial
Small Pharma Inc. has received approval from the U.K. Medicines and Healthcare products Regulatory Authority (MHRA) and the Regional Ethics Committee to initiate a drug interaction clinical trial in the U.K. The clinical trial will assess the interaction between serotonin reuptake inhibitors (SSRIs) and SPL026, the company’s lead N, N-dimethyltryptamine (DMT) candidate, in patients with […]
News and Trends 9 Aug 2022
Relmada Therapeutics gets Fast Track designation for major depressive disorder treatment
Relmada Therapeutics, Inc., a late-stage biotech company addressing diseases of the central nervous system (CNS), has been given U.S. Food and Drug Administration (FDA) Fast Track designation to REL-1017, the company’s novel NMDA receptor (NMDAR) channel blocker, as a monotherapy for the treatment of major depressive disorder (MDD). “The receipt of Fast Track Designation represents […]
News and Trends 5 Jul 2022
Positive news from trial for drug to treat major depressive disorder
A company working on treatments for people with mental health issues has had positive feedback from the development program of an anti-depressant targeting major depressive disorder (MDD). ANeuroTech has just announced that after a successful pre-Investigational New Drug Application (IND) meeting, the US Food and Drug Administration (FDA) has given positive feedback on its […]
ADVERTISEMENT